2022
SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion
2020
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
Galderisi A, Bruschettini M, Russo C, Hall R, Trevisanuto D. Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants. 2020, 12: cd013309. PMID: 33348448, PMCID: PMC8092644, DOI: 10.1002/14651858.cd013309.pub2.Peer-Reviewed Original ResearchConceptsPreterm infantsContinuous glucose monitoringGlycemic measuresRisk ratioIntermittent modalitiesLong-term neurodevelopmental impairmentGlucose monitoringCare Group (EPOC) criteriaCochrane Central RegisterCochrane Effective PracticePrevention of morbidityQuasi-randomized trialStandard search strategyClinical trials databasesLong-term outcomesPreterm infant mortalityAllied Health LiteratureUse of CGMImprecision of estimatesFixed-effects modelCochrane NeonatalAdverse neurodevelopmentCentral RegisterGRADE approachControlled TrialsEffect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi A, Cohen N, Calhoun P, Kraemer K, Breton M, Weinzimer S, Cengiz E. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care 2020, 43: 2146-2152. PMID: 32661108, PMCID: PMC7440894, DOI: 10.2337/dc20-0091.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugEquipment and SuppliesFemaleGlycemic ControlHumansHypoglycemic AgentsInsulin Infusion SystemsInsulin, Regular, HumanMaleMealsPostprandial PeriodYoung AdultConceptsControl armPremeal bolusesPostprandial plasma glucose levelsPostprandial blood glucose controlPrimary efficacy outcomeRapid-acting insulinBlood glucose controlPlasma glucose levelsType 1 diabetesLater time pointsSequential mealsEfficacy outcomesPPG levelsSecondary outcomesGlycemic excursionsMeal studyGlucose controlSubcutaneous routeInsulin delivery systemsGlucose levelsGlucose metricsHigh doseStudy daysInsulin absorptionInsulin bolus